Baxter International Inc. (BAX) Gross Margin: 30.11%
Is Baxter International Inc.’s gross margin high or low?
Baxter International Inc.'s gross margin of 30.11% is 18% below its 5-year average of 36.84%, near the low end of its 5-year range (30.05%–40.06%).
As of Friday, June 12, 2026. 10.80% below its 12-month average of 33.76%.
BAX Gross Margin Chart
BAX Average Gross Margin Chart
BAX Current vs Average Gross Margin Chart
BAX Gross Margin Metrics
GROSS MARGIN
30.11%
GROSS MARGIN AVG TTM
33.76%
GROSS MARGIN AVG 3Y
35.72%
GROSS MARGIN AVG 5Y
36.84%
GROSS MARGIN AVG 10Y
39.11%
GROSS MARGIN AVG 15Y
41.59%
GROSS MARGIN AVG 20Y
43.01%
CURRENT VS TTM AVG
-10.80%
CURRENT VS 3Y AVG
-15.69%
CURRENT VS 5Y AVG
-18.26%
CURRENT VS 10Y AVG
-23.00%
CURRENT VS 15Y AVG
-27.60%
CURRENT VS 20Y AVG
-29.99%
BAX Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Baxter International Inc. (BAX) | $10.70B | 30.11% | 33.76% | 35.72% | 36.84% |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 31.86% | 31.70% | 34.15% | 35.17% |
| Align Technology, Inc. (ALGN) | $12.64B | 67.68% | 69.16% | 69.73% | 70.75% |
| Tempus AI, Inc. (TEM) | $8.65B | 69.55% | 62.30% | 54.75% | 44.45% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.91B | 51.87% | 52.87% | 53.77% | 54.60% |
| Solventum Corporation (SOLV) | $13.72B | 53.67% | 54.56% | 56.03% | 57.27% |
| Hims & Hers Health, Inc. (HIMS) | $6.44B | 67.64% | 76.65% | 78.21% | 76.94% |
| Hologic, Inc. (HOLX) | $16.97B | 52.82% | 58.14% | 57.33% | 59.28% |
| Moderna, Inc. (MRNA) | $19.70B | -13.89% | 54.80% | 53.09% | 65.45% |
| 23andMe Holding Co. (ME) | $15.31M | 53.33% | 48.95% | 47.93% | 47.45% |
Gross Margin Analysis
Gross Margin
30.1%
(Revenue - COGS) / Revenue
Baxter International Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Baxter International Inc. Gross Margin FAQ
- What is the gross margin for Baxter International Inc. (BAX)?
- The gross margin for BAX stock is 30.11%.
- Is Baxter International Inc.'s gross margin high or low?
- Baxter International Inc.'s gross margin of 30.11% is 18% below its 5-year average of 36.84%, near the low end of its 5-year range (30.05%–40.06%).
- What is the TTM average gross margin for Baxter International Inc. (BAX)?
- The TTM average gross margin for BAX stock is 33.76%.
- What is the 3Y average gross margin for Baxter International Inc. (BAX)?
- The 3Y average gross margin for BAX stock is 35.72%.
- What is the 5Y average gross margin for Baxter International Inc. (BAX)?
- The 5Y average gross margin for BAX stock is 36.84%.
- What is the 10Y average gross margin for Baxter International Inc. (BAX)?
- The 10Y average gross margin for BAX stock is 39.11%.
- What is the 15Y average gross margin for Baxter International Inc. (BAX)?
- The 15Y average gross margin for BAX stock is 41.59%.
- What is the 20Y average gross margin for Baxter International Inc. (BAX)?
- The 20Y average gross margin for BAX stock is 43.01%.
Baxter International Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 30.05% |
| 2024-12-31 | 37.46% |
| 2023-12-31 | 40.06% |
| 2022-12-31 | 35.29% |
| 2021-12-31 | 38.86% |
| 2020-12-31 | 39.30% |
| 2019-12-31 | 41.90% |
| 2018-12-31 | 42.88% |
| 2017-12-31 | 42.27% |
| 2016-12-31 | 40.50% |
| 2015-12-31 | 41.59% |
| 2014-12-31 | 42.74% |
| 2013-12-31 | 44.22% |
| 2012-12-31 | 51.19% |
| 2011-12-31 | 50.72% |
| 2010-12-31 | 46.39% |
| 2009-12-31 | 51.94% |
| 2008-12-31 | 49.64% |
| 2007-12-31 | 49.00% |
| 2006-12-31 | 45.64% |
| 2005-12-31 | 41.56% |
| 2004-12-31 | 41.17% |
| 2003-12-31 | 44.40% |
| 2002-12-31 | 46.73% |
| 2001-12-31 | 46.38% |
| 2000-12-31 | 45.63% |
| 1999-12-31 | 49.61% |
| 1998-12-31 | 50.65% |
| 1997-12-31 | 51.13% |
| 1996-12-31 | 50.40% |
Related Metrics
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Andrew Hider